EMEA-002360-PIP01-18-M02
Key facts
| Active substance |
Tirzepatide
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0174/2022
|
| PIP number |
EMEA-002360-PIP01-18-M02
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Eli Lilly and Company Ltd
Email: EU_PAEDIATRIC@LILLY.COM |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|